IMRN

Immuron Limited

2.42 USD
+0.19 (+8.52%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immuron Limited stock is up 7.56% since 30 days ago. The next earnings date is Jul 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 7 June’s closed higher than May.

About Immuron Limited

Immuron Limited researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials.